Skip to content

Comparison of Different Protocols of Fluid Therapy in Severe Preeclamptic Patients Under Spinal Anesthesia

Comparison of Two Different Protocols of Fluid Therapy in Severe Preeclamptic Patients Under Spinal Anesthesia : Hemodynamic and Kidney Function Outcome

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03478618
Enrollment
60
Registered
2018-03-27
Start date
2018-03-31
Completion date
2019-04-30
Last updated
2018-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypotension Drug-Induced

Brief summary

To compare the effect of two different protocol of fluid therapy in sever preeclamptic patients under spinal anesthesia : Hemodynamic and kidney function .

Interventions

Patients will be divided into 2 groups according to the amount of fluids received during caesarian section under spinal anesthesia. Group (R) 30 patients will receive 15ml/kg/h lactated Ringer (LR) intraoperative. Group (L) 30 patients will receive 30ml/kg/h lactated Ringer (LR) intraoperative. blood loss will be replaced if more than 500 ml in ratio 3 ml crystalloid : 1ml blood in both groups

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* more than 36 weeks gestation * singleton pregnant women planned for elective caesarian section

Exclusion criteria

* patient refusal. * psychiatric disorders. * parturient \<36 weeks gestation, twins, abnormal cardiotocography (CTG) tracing. * absolute contraindications for spinal anesthesia (patients refusal, raised intracranial pressure, hypovolemic states, abnormal coagulopathy).

Design outcomes

Primary

MeasureTime frameDescription
incidence of hypotension1 hourdecrease in systolic blood pressure more than 20% of base line

Contacts

Primary ContactZein El Abadin Zarae Hassan, PhD
zein20002002@yahoo.com01005187371

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026